Colucid Pharmaceuticals, Inc. (CLCD): Thomas P. Mathers , Chief Executive Officer of Colucid Pharmaceuticals, Inc. sold 1,502 shares on Jul 5, 2016. The Insider selling transaction was reported by the company on Jul 5, 2016 to the Securities and Exchange Commission. The shares were sold at $9.73 per share for a total value of $14,614.46 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 30, 2016, Raymond Skwierczynski (Head,Pharmaceutical Operations) sold 516 shares at $7.01 per share price.On Jun 7, 2016, Thomas P. Mathers (Chief Executive Officer) sold 1,502 shares at $7.25 per share price.Also, On May 12, 2015, A/s Novo (10% owner) purchased 1,300,000 shares at $10.00 per share price.
CoLucid Pharmaceuticals Inc: On Friday, Jul 1, 2016 heightened volatility was witnessed in CoLucid Pharmaceuticals Inc which led to swings in the share price. The shares opened for trading at $8.28 and hit $10.04 on the upside , eventually ending the session at $9.62, with a gain of 17.75% or 1.45 points. The heightened volatility saw the trading volume jump to 1,07,771 shares. The 52-week high of the share price is $10.04 and the company has a market cap of $147 M . The 52-week low of the share price is at $3.57.
CoLucid Pharmaceuticals Inc. is a United States-based clinical-stage biopharmaceutical company that develops a product candidate Lasmiditan for the treatment of central nervous system (CNS) disorders. The Company develops oral Lasmiditan for the acute treatment of migraine headaches in adults and intravenous Lasmiditan for the acute treatment of unspecified headache pain in adults in emergency room and other urgent care settings. Its Lasmiditan is used for the acute treatment of migraine headaches in adults without the vasoconstrictor activity associated with previous generations of migraine therapies. The Company has completed seven clinical studies for Lasmiditan including a TQTc study and a Phase IIb study treating a single migraine attack in around 391 patients.